Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets.
Gonzalez Barca E, Tomás-Roca L, Esteve A, Rodriguez M, Gato L, Alonso-Alonso R, Martin Garcia-Sancho A, Cordoba R, Monter-Rovira A, Bastos-Oreiro M, Bergua Burgues JM, Sayas MJ, Viguria Alegria MC, Sanchez-Blanco JJ, Roig Pellicer M, Luzardo Henriquez HD, de Oña R, Cabezudo ME, Infante MS, Queizán Hernández JA, Sanz-Pamplona R, Blanco O, Mozos A, Climent F, Piris MA. Gonzalez Barca E, et al. Am J Hematol. 2023 Jun;98(6):E134-E138. doi: 10.1002/ajh.26904. Epub 2023 Mar 16. Am J Hematol. 2023. PMID: 36882876
Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study.
Gros L, Roldán A, Cabero-Martínez A, Domínguez-Pinilla N, de la Fuente A, González-Barca E, Tasso M, Torrent M, Gallardo E, Del Cerro I, Giró-Perafita A, Badia X. Gros L, et al. Among authors: gonzalez barca e. J Oncol Pharm Pract. 2023 Jun;29(4):794-801. doi: 10.1177/10781552221079568. Epub 2022 Feb 11. J Oncol Pharm Pract. 2023. PMID: 35147457 Free PMC article.
Multiplex ligation-dependent probe amplification for detection of genomic alterations in chronic lymphocytic leukaemia.
Coll-Mulet L, Santidrián AF, Cosialls AM, Iglesias-Serret D, de Frias M, Grau J, Menoyo A, González-Barca E, Pons G, Domingo A, Gil J. Coll-Mulet L, et al. Among authors: gonzalez barca e. Br J Haematol. 2008 Sep;142(5):793-801. doi: 10.1111/j.1365-2141.2008.07268.x. Epub 2008 Jun 17. Br J Haematol. 2008. PMID: 18564355 Free article.
Established and suggested exposures on CLL/SLL etiology: Results from the CLL-MCC-Spain study.
Benavente Y, Casabonne D, Costas L, Robles C, Alonso E, de la Banda E, Gonzalez-Barca E, Marcos-Gragera R, Llorca J, Tardón A, Monleon JJ, Aymerich M, Campo E, Gimeno-Vázquez E, Castaño-Vinyals G, Aragonés N, Pollán M, Kogevinas M, de Sanjosé S. Benavente Y, et al. Among authors: gonzalez barca e. Cancer Epidemiol. 2018 Feb;52:106-111. doi: 10.1016/j.canep.2017.12.012. Epub 2018 Jan 4. Cancer Epidemiol. 2018. PMID: 29289901 Clinical Trial.
A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection.
Parody R, Sánchez-Ortega I, Mussetti A, Patiño B, Arnan M, Pomares H, González-Barca E, Mercadal S, Boqué C, Maluquer C, Carro I, Peña M, Clapés V, Verdesoto S, Bustamante G, Oliveira AC, Baca C, Cabezudo E, Talarn C, Escoda L, Ortega S, García N, Isabel González-Medina M, Sánchez-Salmerón M, Fusté C, Villa J, Carreras E, Domingo-Domènech E, Sureda A. Parody R, et al. Among authors: gonzalez barca e. Bone Marrow Transplant. 2022 Feb;57(2):176-182. doi: 10.1038/s41409-021-01506-4. Epub 2021 Oct 28. Bone Marrow Transplant. 2022. PMID: 34711917
Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.
Vallejo C, Ríos E, de la Serna J, Jarque I, Ferrá C, Sánchez-Godoy P, Solano C, de la Cámara R, Rosell AI, Varela R, García MD, González-Barca E, López J, Pérez E, Ferrer S, Casado LF, Vázquez L, Villalón L, García-Marco JA. Vallejo C, et al. Among authors: gonzalez barca e. Expert Rev Hematol. 2011 Feb;4(1):9-16. doi: 10.1586/ehm.10.77. Expert Rev Hematol. 2011. PMID: 21322774
Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.
González-Barca E, Canales M, Cortés M, Vidal MJ, Salar A, Oriol A, Bargay J, Bello JL, Sánchez JJ, Tomás JF, Donato E, Ferrer S, Caballero D; GELTAMO (Grupo Español de Linfoma y Trasplante de Médula Ósea). González-Barca E, et al. Nucl Med Commun. 2013 Oct;34(10):946-52. doi: 10.1097/MNM.0b013e328363c695. Nucl Med Commun. 2013. PMID: 23880897 Clinical Trial.
157 results